Buprenorphine for the Neonatal Abstinence Syndrome

To the Editor: Kraft et al. (June 15 issue) 1 report that in the Blinded Buprenorphine or Neonatal Morphine Solution (BBORN) trial, the duration of treatment in infants with the neonatal abstinence syndrome was shorter with buprenorphine than with morphine. I am concerned that these findings do not account for the likely effects of 30% ethanol in their standard buprenorphine solution. Ethanol is a well-known facilitator of the γ-aminobutyric acid receptor, and its inclusion (one assumes to facilitate the stability of the solution) may have had an effect on the outcome of the trial. It seems to me that Kraft et . . .